Cellular and antibody response in GMZ2-vaccinated Gabonese volunteers in a controlled human malaria infection trial

[1]  Visopo Harawa,et al.  Optimization of stimulation and staining conditions for intracellular cytokine staining (ICS) for determination of cytokine-producing T cells and monocytes , 2021, Current research in immunology.

[2]  S. Hoffman,et al.  Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial , 2021, Nature Communications.

[3]  E. Eisemann,et al.  Systems analysis and controlled malaria infection in Europeans and Africans elucidate naturally acquired immunity , 2021, Nature Immunology.

[4]  S. Hoffman,et al.  Effect of immune regulatory pathways after immunization with GMZ2 malaria vaccine candidate in healthy lifelong malaria-exposed adults. , 2020, Vaccine.

[5]  Qingyuan Du,et al.  Candidate , 2012, Juan Perón.

[6]  S. Hoffman,et al.  Controlled human malaria infection of healthy lifelong malaria-exposed adults to assess safety, immunogenicity and efficacy of the asexual blood stage malaria vaccine candidate GMZ2. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  D. Hansen,et al.  Development of B Cell Memory in Malaria , 2019, Front. Immunol..

[8]  J. Stevenson,et al.  Distinct Antibody Signatures Associated with Different Malaria Transmission Intensities in Zambia and Zimbabwe , 2019, mSphere.

[9]  Arlo Z. Randall,et al.  Antibody Biomarkers Associated with Sterile Protection Induced by Controlled Human Malaria Infection under Chloroquine Prophylaxis , 2019, mSphere.

[10]  S. Kappe,et al.  Natural Parasite Exposure Induces Protective Human Anti‐Malarial Antibodies , 2017, Immunity.

[11]  S. Hoffman,et al.  Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon , 2017, The American journal of tropical medicine and hygiene.

[12]  J. Harezlak,et al.  Distinct Helper T Cell Type 1 and 2 Responses Associated With Malaria Protection and Risk in RTS,S/AS01E Vaccinees , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Sumana Chakravarty,et al.  Sterile protection against human malaria by chemoattenuated PfSPZ vaccine , 2017, Nature.

[14]  M. Christiansen,et al.  A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children. , 2016, Vaccine.

[15]  R. Rappuoli,et al.  Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens , 2016, Scientific Reports.

[16]  R. Verity,et al.  Vaccine approaches to malaria control and elimination: Insights from mathematical models. , 2015, Vaccine.

[17]  Arlo Z. Randall,et al.  Plasmodium falciparum Protein Microarray Antibody Profiles Correlate With Protection From Symptomatic Malaria in Kenya. , 2015, The Journal of infectious diseases.

[18]  Arlo Z. Randall,et al.  Biosignatures of Exposure/Transmission and Immunity , 2015, The American journal of tropical medicine and hygiene.

[19]  S. Hoffman,et al.  Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates , 2015, Malaria Journal.

[20]  Peter D. Crompton,et al.  Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities , 2015, Proceedings of the National Academy of Sciences.

[21]  Greg Finak,et al.  COMPASS identifies T-cell subsets correlated with clinical outcomes , 2015, Nature Biotechnology.

[22]  S. Hoffman,et al.  Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres , 2015, Malaria Journal.

[23]  T. Ottenhoff,et al.  A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. , 2014, Vaccine.

[24]  A. Larbi,et al.  CMV Latent Infection Improves CD8+ T Response to SEB Due to Expansion of Polyfunctional CD57+ Cells in Young Individuals , 2014, PloS one.

[25]  D. Molina,et al.  Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis , 2013, Scientific Reports.

[26]  Lorne A. Babiuk,et al.  Mechanisms of Action of Adjuvants , 2013, Front. Immunol..

[27]  R. Noor,et al.  A Randomized Controlled Phase Ib Trial of the Malaria Vaccine Candidate GMZ2 in African Children , 2011, PloS one.

[28]  Joe D. Cohen,et al.  Protective Immunity Induced with the RTS,S/AS Vaccine Is Associated with IL-2 and TNF-α Producing Effector and Central Memory CD4+ T Cells , 2011, PloS one.

[29]  G. Ireton,et al.  A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate. , 2011, Vaccine.

[30]  M. Demoitié,et al.  Induction of Plasmodium falciparum-Specific CD4+ T Cells and Memory B Cells in Gabonese Children Vaccinated with RTS,S/AS01E and RTS,S/AS02D , 2011, PloS one.

[31]  R. Noor,et al.  Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon. , 2010, Vaccine.

[32]  A. Sher,et al.  IL-10 production by CD4+ effector T cells: a mechanism for self-regulation , 2010, Mucosal Immunology.

[33]  B. Mordmüller,et al.  Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate. , 2009, Vaccine.

[34]  P. Andersen,et al.  A Novel Liposome-Based Adjuvant CAF01 for Induction of CD8+ Cytotoxic T-Lymphocytes (CTL) to HIV-1 Minimal CTL Peptides in HLA-A*0201 Transgenic Mice , 2009, PloS one.

[35]  V. A. Stewart,et al.  Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. , 2009, The Journal of infectious diseases.

[36]  Peter D. Crompton,et al.  Atypical Memory B Cells Are Greatly Expanded in Individuals Living in a Malaria-Endemic Area1 , 2009, The Journal of Immunology.

[37]  P. Andersen,et al.  Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by Multifunctional CD4 Memory T Cells1 , 2009, The Journal of Immunology.

[38]  G. Smyth,et al.  Microarray background correction: maximum likelihood estimation for the normal–exponential convolution , 2008, Biostatistics.

[39]  Arlo Z. Randall,et al.  Profiling humoral immune responses to P. falciparum infection with protein microarrays , 2008, Proteomics.

[40]  Jacques-Olivier Pers,et al.  The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. , 2008, Blood.

[41]  Nichole E Carlson,et al.  Duration of humoral immunity to common viral and vaccine antigens. , 2007, The New England journal of medicine.

[42]  Mario Roederer,et al.  Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major , 2007, Nature Medicine.

[43]  M. Wahlgren,et al.  Identification of a Polyclonal B-Cell Activator in Plasmodium falciparum , 2004, Infection and Immunity.

[44]  M. Theisen,et al.  A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. , 2004, Vaccine.

[45]  W. Ripley Ballou,et al.  Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ1 , 2003, The Journal of Immunology.

[46]  David Gray,et al.  Immunological Memory and Protective Immunity: Understanding Their Relation , 1996, Science.

[47]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[48]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..